N-[[4-(cyclopropylsulfonylamino)-2-pyridinyl]methyl]-5-(6-methoxypyrazin-2-yl)pyridine-2-carboxamide
C20H20N6O4S — CID 163271317
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[[4-(cyclopropylsulfonylamino)-2-pyridinyl]methyl]-5-(6-methoxypyrazin-2-yl)pyridine-2-carboxamide
N-[[4-(cyclopropylsulfonylamino)-2-pyridinyl]methyl]-5-(6-methoxypyrazin-2-yl)pyridine-2-carboxamide (PubChem CID 163271317) has the molecular formula C20H20N6O4S and a molecular weight of 440.49 g/mol. Its IUPAC name is N-[[4-(cyclopropylsulfonylamino)-2-pyridinyl]methyl]-5-(6-methoxypyrazin-2-yl)pyridine-2-carboxamide.
Molecular Properties
| Compound Name | N-[[4-(cyclopropylsulfonylamino)-2-pyridinyl]methyl]-5-(6-methoxypyrazin-2-yl)pyridine-2-carboxamide |
|---|---|
| PubChem CID | 163271317 |
| Molecular Formula | C20H20N6O4S |
| Molecular Weight | 440.49 g/mol |
| Exact Mass | 440.13 |
| IUPAC Name | N-[[4-(cyclopropylsulfonylamino)-2-pyridinyl]methyl]-5-(6-methoxypyrazin-2-yl)pyridine-2-carboxamide |
| SMILES | COc1cncc(-c2ccc(C(=O)NCc3cc(NS(=O)(=O)C4CC4)ccn3)nc2)n1 |
| InChI | InChI=1S/C20H20N6O4S/c1-30-19-12-21-11-18(25-19)13-2-5-17(23-9-13)20(27)24-10-15-8-14(6-7-22-15)26-31(28,29)16-3-4-16/h2,5-9,11-12,16H,3-4,10H2,1H3,(H,22,26)(H,24,27) |
| InChIKey | QNXNGQCTOYZTGZ-UHFFFAOYSA-N |
| XLogP | 1.78 |
| TPSA | 136.06 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 440.49 |
| LogP ≤ 5 | 1.78 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 163271317 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.